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Circulating Tumor DNA to Monitor Metastatic Breast Cancer
To the Editor: Dawson et al. (March 28 issue)1 
suggest that the detection of circulating tumor 
DNA in 58% of patients with metastatic breast 
cancer can be used as an effective indicator of 
tumor load during treatment with standard sys-
temic therapies. The study does not address the 
clinical utility of circulating tumor DNA. More-
over, the authors claim that circulating tumor 
DNA represents a more effective monitoring tool 
than the enumeration of circulating tumor cells. 
This statement is incorrect, considering that the 
enumeration of circulating tumor cells proved 
the ability to predict prognosis and monitor 
treatment efficacy in all patients with metastatic 
breast cancer, regardless of disease subtype.2 
Furthermore, new detection methods describe 
the molecular heterogeneity and measure dy-
namic phenotypic changes in circulating tumor 
cells during metastasis.3,4 We propose that circu-
lating tumor DNA provides a complementary 
method in the assessment of patients with de-
tectable mutations and should be more appropri-
ately used to select and monitor molecularly tar-
geted therapies. Combined diagnostic methods 
will provide a more effective approach than each 
method alone to the implementation of precision 
medicine and improved clinical outcomes.
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To the Editor: Dawson et al. propose circulat-
ing tumor DNA as a new biomarker for meta-
static breast cancer. In our opinion, the timing of 
the analysis is crucial for the correct interpreta-
tion of such data obtained from samples acquired 
during chemotherapy.
Apoptosis leads to the augmented release of 
cell-free DNA,1 so chemotherapy is expected to 
temporarily increase the levels of circulating 
tumor DNA. Thus, the assumption that such 
increases reflect tumor load may be incorrect, 
depending on the time point chosen.
We suggest a dual role for analysis with cir-
culating tumor DNA. First, the difference be-
tween basal levels before and peak levels after 
the administration of chemotherapy may serve 
as an indicator of tumor responsiveness. Second, 
levels of circulating tumor DNA measured sev-
eral days after the last chemotherapy cycle may 
serve as a surrogate marker for total tumor mass.
Analysis of the kinetics of circulating tumor 
DNA during the use of various chemotherapeutic 
drugs and regimens may pave the way for the 
clinical translation of analysis with circulating 
tumor DNA.
Lukas Weiss, M.D., Ph.D. 
Clemens Hufnagl, M.Sc. 
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The Authors Reply: We support the idea that 
combined methods involving circulating tumor 
cells and circulating tumor DNA could be used to 
analyze tumor status and changes. By the crite-
rion of sensitivity for detection of disease bur-
den, our data clearly show an advantage to the 
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detection of circulating tumor DNA over the 
enumeration of circulating tumor cells by 
means of the CellSearch System. Our findings 
provide the rationale for future studies to ad-
dress the full clinical utility of analyses with 
circulating tumor DNA.
One apparent limitation of our work was that 
only two genes (PIK3CA and TP53) were analyzed 
for most patients. These are the two most com-
monly mutated genes in breast cancer, and as 
expected, they were informative in half the pa-
tients recruited. This does not represent a gen-
eral limitation of circulating tumor DNA: as a 
proof of principle, we also found that we were 
able to monitor other somatic mutations and 
structural variants in a subset of patients who 
did not have mutations in PIK3CA or TP53. Our 
data indicate that any cancer-specific mutation 
can be monitored in circulating tumor DNA 
from patients with metastatic breast cancer.
The timing of blood and plasma collection is 
obviously an important variable. In our study, all 
samples were collected immediately before the 
administration of each treatment cycle. The pos-
sibility of measuring an increase in the release 
of circulating tumor DNA as an indicator of re-
sponsiveness is attractive and is supported by 
xenograft models.1 
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Globalization, Climate Change, and Human Health
To the Editor: The scholarly review of global-
ization and climate change by McMichael (April 
4 issue)1 emphasizes the associated economic, 
social, demographic, and environmental threats 
to human health and suggests steps to mitigate 
these changes on a global scale. Although McMi-
chael also mentions the effects of climate change 
and globalization on the geographic range of 
vectorborne infections, he does not alert readers 
to sobering examples of the emergence of tropi-
cal infections in the temperate zone (Table 1). 
Globalization and climate change promote the 
emergence of these infections synergistically. 
Globalization increases the number of infected 
travelers and the accidental importation of in-
fected vectors. Climate change warms the envi-
ronment to temperatures that permit reproduc-
tion of the vector and parasite. Increasing 
Table 1. Effects of Globalization and Climate Change on the Spread of Tropical Infections to the Temperate Zone.*
Tropical 
Infection Areas of Local Transmission Comment Reference
Dengue Key West and elsewhere in Florida; 
Brownsville, Texas; France; and 
Croatia and other areas of 
 southern Europe
A total of 5% of Key West residents 
have antibodies against dengue, 
and locally transmitted infections 
have been reported in other  
counties, including Miami–Dade; 
39% of residents in Brownsville 
have antibodies against dengue
Jordan et al.,2  
Ramos et al.,3 
Butler4
Malaria Greece The CDC recommends precautions 
(level 1) for persons who travel to 
Greece, including consideration of 
drug prophylaxis for travel to some 
regions
CDC5
Chikungunya Italy and France Hundreds of persons have been   
infected in Italy
Butler4
* CDC denotes Centers for Disease Control and Prevention. 
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